Lilly reports positive top line data for TOGETHER-PsO Phase IIIb trial
The trial enrolled 274 adults evenly assigned to receive subcutaneous Taltz alone or combined with Zepbound.
19 February 2026
19 February 2026
The trial enrolled 274 adults evenly assigned to receive subcutaneous Taltz alone or combined with Zepbound.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.